Home › Research › Treatments
Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study
Torres-Yaghi Y, Chrones L, Abler V, Brunson G. BMC Neurology, 2025-11-24
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Pimavanserin is approved by the US Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease. We analyzed the effect of pimavanserin on psychosis in patients with Lewy body dementia, including Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), from the phase 3 HARMONY trial. Methods This subgroup analysis included patients with PDD or DLB from HARMONY, a previously completed, multicenter, randomized, discontinuation study of pimavanserin for dementia-related psychosis. Patients with moderate to severe psychosis received pimavanserin 34 mg once daily for 12 weeks (open-label treatment). Those who achieved a sustained response at weeks 8 and 12 were randomized to continue treatment with pimavanserin or discontinue treatment and receive placebo for up to 26 weeks in the double-blind period. The primary endpoint was the time to psychosis relapse as defined by prespecified criteria. Safety was evaluated by adverse events; effects on motor symptoms and cognitive abilities were also assessed. Results Overall, 392 patients were enrolled in HARMONY; 49 patients with PDD and 27 patients with DLB were included in the open-label safety analysis, of whom 46 met response criteria and were randomized to receive pimavanserin (n = 22) or placebo (n = 24) during the double-blind period. Psychosis relapse risk was significantly lower with pimavanserin vs. placebo (hazard ratio, 0.031; 95% CI, 0.010-0.103; 2-sided nominal P Conclusions Psychosis relapse risk was significantly lower with pimavanserin vs. placebo in patients with Lewy body dementia. Pimavanserin was also well tolerated and did not worsen motor or cognitive function. Results should be interpreted cautiously since this study is a post hoc analysis of a previous trial that was not originally designed or powered to draw clinical conclusions based on dementia subgroups. Trial registration ClinicalTrials.gov Identifier: NCT03325556 (registered 18 October 2017).
What this study adds
Evidence grade: Early
The record lists 76 participants. In this subgroup analysis of the HARMONY trial, pimavanserin was associated with a significantly lower risk of psychosis relapse in patients with Lewy body dementia. Reported effect size: Psychosis relapse HR 0.031 (95% CI 0.010-0.103) vs placebo among 46 randomised responders.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Torres-Yaghi, Y., Chrones, L., Abler, V., & Brunson, G. (2025). Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study. BMC Neurology. https://doi.org/10.1186/s12883-025-04496-8
Vancouver
Torres-Yaghi Y, Chrones L, Abler V, Brunson G. Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study. BMC Neurology. 2025. doi:10.1186/s12883-025-04496-8. PMID: 41286676.
BibTeX
@article{torresyaghi2025-41286676,
author = {Torres-Yaghi, Y. and Chrones, L. and Abler, V. and Brunson, G.},
title = {{Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study}},
journal = {BMC Neurology},
year = {2025},
doi = {10.1186/s12883-025-04496-8},
pmid = {41286676},
url = {https://doi.org/10.1186/s12883-025-04496-8}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Background Pimavanserin is approved by the US Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease.
- Results Overall, 392 patients were enrolled in HARMONY; 49 patients with PDD and 27 patients with DLB were included in the open-label safety analysis, of whom 46 met response criteria and were randomized to receive pimavanserin (n = 22) or placebo (n = 24) during the double-blind period.
- Psychosis relapse risk was significantly lower with pimavanserin vs. placebo (hazard ratio, 0.031; 95% CI, 0.010-0.103; 2-sided nominal P Conclusions Psychosis relapse risk was significantly lower with pimavanserin vs. placebo in patients with Lewy body dementia.
- Results should be interpreted cautiously since this study is a post hoc analysis of a previous trial that was not originally designed or powered to draw clinical conclusions based on dementia subgroups.
Why it matters
In this subgroup analysis of the HARMONY trial, pimavanserin was associated with a significantly lower risk of psychosis relapse in patients with Lewy body dementia. The analysis included a small number of patients with Parkinson's disease dementia or dementia with Lewy bodies.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designphase-3-trial
- Participants76
- Effect sizePsychosis relapse HR 0.031 (95% CI 0.010-0.103) vs placebo among 46 randomised responders
- Evidence strengthEarly
Limitations
Post hoc subgroup analysis not powered for these dementia types; only 46 randomised; enriched design (only responders randomised) inflates apparent effect; industry-sponsored; pimavanserin carries a boxed warning for mortality in dementia-related psychosis.
How this study scored 49/100
Published in a peer-reviewed journal, and it is a large phase 3 trial. We have no data on senior author's track record and free to read, so those were left out: it earned 46 of the 94 points we could judge it on, which is 49 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (BMC Neurology) |
| Journal's citation record | 1 / 4 | BMC Neurology: journal h-index 122 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 76 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Greg Brunson holds only 4 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Georgetown University Medical Center: institution h-index 564 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41286676) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 46 / 94 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 46 of the 94 points we could judge it on is 49 out of 100. |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.